Everest Medicines FY2025 net loss narrows to RMB298 million; revenue more than doubled to RMB1.7 billion

Reuters

11 hours ago

Everest Medicines FY2025 net loss narrows to RMB298 million; revenue more than doubled to RMB1.7 billion

Everest Medicines published an annual results announcement for the year ended Dec. 31, 2025.
Revenue was RMB1.71 billion, more than tripled, driven mainly by the continued ramp-up of NEFECON following its inclusion in China’s NRDL.
Gross profit margin was 69.3%, down 5.3 percentage points, reflecting NEFECON’s NRDL pricing in Chinese Mainland.
Net loss was RMB297.8 million, down 71.4%, attributed to revenue growth, improved efficiency, deferred tax asset recognition in Singapore, and RMB312.3 million of impairment losses on intangible assets.
Cash and cash equivalents and bank deposits were RMB2.73 billion, and adjusted profit was RMB187.2 million; management said it plans to pursue NRDL negotiations in 2H 2026 for VELSIPITY and XERAVA and expects to submit a China BLA in 1H 2026 for LEROCHOL.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Everest Medicines Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260326-12067963), on March 25, 2026, and is solely responsible for the information contained therein.

At the request of the copyright holder, you need to log in to view this content

LOGIN / SIGN UP

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2622882758"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2622882758\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2622882758?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-26 06:55","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2622882758","market":"fut","top_or_hot":-1,"title":"Everest Medicines FY2025 net loss narrows to RMB298 million; revenue more than doubled to RMB1.7 billion","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Everest Medicines FY2025 net loss narrows to RMB298 million; revenue more than doubled to RMB1.7 billion\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<ul>\n<li>\n          Everest Medicines published an annual results announcement for the year ended Dec. 31, 2025.\n        </li>\n<li>\n          Revenue was RMB1.71 billion, more than tripled, driven mainly by the continued ramp-up of NEFECON following its inclusion in China’s NRDL.\n        </li>\n<li>\n          Gross profit margin was 69.3%, down 5.3 percentage points, reflecting NEFECON’s NRDL pricing in Chinese Mainland.\n        </li>\n<li>\n          Net loss was RMB297.8 million, down 71.4%, attributed to revenue growth, improved efficiency, deferred tax asset recognition in Singapore, and RMB312.3 million of impairment losses on intangible assets.\n        </li>\n<li>\n          Cash and cash equivalents and bank deposits were RMB2.73 billion, and adjusted profit was RMB187.2 million; management said it plans to pursue NRDL negotiations in 2H 2026 for VELSIPITY and XERAVA and expects to submit a China BLA in 1H 2026 for LEROCHOL.\n        </li>\n</ul>\n<br/>\n<br/>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Everest Medicines Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260326-12067963), on March 25, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Everest Medicines FY2025 net loss narrows to RMB298 million; revenue more than doubled to RMB1.7 billion</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nEverest Medicines FY2025 net loss narrows to RMB298 million; revenue more than doubled to RMB1.7 billion\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-03-26 06:55</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Everest Medicines FY2025 net loss narrows to RMB298 million; revenue more than doubled to RMB1.7 billion\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<ul>\n<li>\n          Everest Medicines published an annual results announcement for the year ended Dec. 31, 2025.\n        </li>\n<li>\n          Revenue was RMB1.71 billion, more than tripled, driven mainly by the continued ramp-up of NEFECON following its inclusion in China’s NRDL.\n        </li>\n<li>\n          Gross profit margin was 69.3%, down 5.3 percentage points, reflecting NEFECON’s NRDL pricing in Chinese Mainland.\n        </li>\n<li>\n          Net loss was RMB297.8 million, down 71.4%, attributed to revenue growth, improved efficiency, deferred tax asset recognition in Singapore, and RMB312.3 million of impairment losses on intangible assets.\n        </li>\n<li>\n          Cash and cash equivalents and bank deposits were RMB2.73 billion, and adjusted profit was RMB187.2 million; management said it plans to pursue NRDL negotiations in 2H 2026 for VELSIPITY and XERAVA and expects to submit a China BLA in 1H 2026 for LEROCHOL.\n        </li>\n</ul>\n<br/>\n<br/>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Everest Medicines Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260326-12067963), on March 25, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1574","symbol_name":"生物医药B类股","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260325:nNDL4gxd68:1","article_id":"2622882758","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2622882758","pubTimestamp":1774479323,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Everest Medicines published an annual results announcement for the year ended Dec. 31, 2025.Revenue was RMB1.71 billion, more than tripled, driven mainly by the continued ramp-up of NEFECON following its inclusion in China’s NRDL.Net loss was RMB297.8 million, down 71.4%, attributed to revenue growth, improved efficiency, deferred tax asset recognition in Singapore, and RMB312.3 million of impairment losses on intangible assets.Cash and cash equivalents and bank deposits were RMB2.73 billion, and adjusted profit was RMB187.2 million; management said it plans to pursue NRDL negotiations in 2H 2026 for VELSIPITY and XERAVA and expects to submit a China BLA in 1H 2026 for LEROCHOL.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Everest Me","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK1574":"生物医药B类股","BK1583":"高瓴概念","01952":"云顶新耀","BK1161":"生物科技"},"translate_title":"Everest Medicines 2025财年净亏损收窄至人民币2.98亿元；收入增长逾一倍至人民币17亿元","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01952":0.9},"content_text":"Everest Medicines FY2025 net loss narrows to RMB298 million; revenue more than doubled to RMB1.7 billion\n    \n\n\n          Everest Medicines published an annual results announcement for the year ended Dec. 31, 2025.\n        \n\n          Revenue was RMB1.71 billion, more than tripled, driven mainly by the continued ramp-up of NEFECON following its inclusion in China’s NRDL.\n        \n\n          Gross profit margin was 69.3%, down 5.3 percentage points, reflecting NEFECON’s NRDL pricing in Chinese Mainland.\n        \n\n          Net loss was RMB297.8 million, down 71.4%, attributed to revenue growth, improved efficiency, deferred tax asset recognition in Singapore, and RMB312.3 million of impairment losses on intangible assets.\n        \n\n          Cash and cash equivalents and bank deposits were RMB2.73 billion, and adjusted profit was RMB187.2 million; management said it plans to pursue NRDL negotiations in 2H 2026 for VELSIPITY and XERAVA and expects to submit a China BLA in 1H 2026 for LEROCHOL.\n        \n\n\n\n\n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Everest Medicines Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260326-12067963), on March 25, 2026, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}